Skip to content
Resolve Therapeutics, LLC.
Resolve Therapeutics, LLC.Resolve Therapeutics, LLC.
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News

Category Archives: News

Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial

NewsBy Development TeamNovember 14, 2022

St. Petersburg, FL – November 7, 2022 – Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that its phase 2 clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121).

Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patients

NewsBy Development TeamJune 23, 2021

St. Petersburg, FL–June 23, 2021–Resolve Therapeutics, pioneeringfirst–in–class,targeted, safetherapiesfor underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV–132 to initiate a phase 2 clinical trial in patients with long covid.

RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial

NewsBy James PosadaDecember 8, 2020

RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial

Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results

NewsBy James PosadaDecember 8, 2020

Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results

Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus

NewsBy James PosadaJuly 22, 2019

Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus

Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome

NewsBy James PosadaJune 13, 2019

Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome

Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology

NewsBy James PosadaJune 10, 2019

Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology

Resolve Therapeutics Announces Publication of Clinical Data Demonstrating the Role of Circulating RNA in Systemic Lupus Erythematosus

NewsBy James PosadaAugust 22, 2016

Resolve Therapeutics Announces Publication of Clinical Data Demonstrating the Role of Circulating RNA in Systemic Lupus Erythematosus

Resolve to Present Data on Lupus Studies at International Rheumatology Conference

NewsBy James PosadaMay 26, 2016

Resolve to Present Data on Lupus Studies at International Rheumatology Conference

Resolve Announces Positive Clinical Data from RSLV-132 Lupus Study

NewsBy James PosadaFebruary 10, 2016

Resolve Announces Positive Clinical Data from RSLV-132 Lupus Study

→12→
© 2020 Resolve Therapeutics. All rights reserved.

Sitemap   Terms of Use   Privacy Policy  

Go to Top